ABOUT DIAMYD MEDICAL
ABOUT DIAMYD MEDICAL
The Diamyd Story
CEO Comments
Board & Management
Scientific Advisory Board
Corporate Governance
Annual General Meeting
Board & Management
Auditors
Articles of Incorporation
Remuneration Principles
Incentive Programs
Partnering
Contact Us
DIABETES
DIABETES
Type 1
LADA
Type 2
Complications
PRODUCTS & PIPELINE
PRODUCTS & PIPELINE
GAD platform
Diamyd
®
Diamyd
®
in Type 1
Diamyd
®
in LADA
Order GAD for research
CLINICAL TRIALS
CLINICAL TRIALS
Clinical development
Diabetes Clinical Trials
Drug Development
INVESTOR RELATIONS
INVESTOR RELATIONS
Press Releases
Financial Reports
Calendar
Owners
Share Trading
Insider Trading
Company Description
Tax Agency Information
PRESS ROOM
PRESS ROOM
Press Releases
Events & Mediawatch
Scientific publications
Webcasts/Podcasts
Newsletter Subscription
Media Contact
This website is only intended for investors
Fighting diabetes
Diamyd Medical is a diabetes company active in the field of pharmaceutical development. The Company is headquartered in Stockholm, Sweden and shares are listed on NASDAQ OMX First North (ticker: DMYD B).
With the new venture Diamyd Medical enters the expansive field of stem cells.
Diabetes − a chronic disease
Diabetes is associated with serious complications due to elevated and fluctuating blood sugar levels, causing substantial suffering and extensive costs for society.
CEO Comments
Recent times have been eventful for Diamyd Medical and we were able to report two items of good news in quick succession the past week. Together with a group of founding partners and Karolinska Institutet...
Diamyd
®
− The Diabetes Vaccine
Diamyd
®
is a GAD-based therapy under development for the treatment and prevention of autoimmune diabetes such as type 1 diabetes and LADA. Treatment with Diamyd
®
aims to intervene in the autoimmune...
Pressmeddelanden
03 april 2014, 08:30
Diamyd Medical träder in i stamcellsfältet genom investering i svensk navelsträngsblodbank
02 april 2014, 13:06
Diamyd Medicals tidigare systerbolag säkrar ny finansiering
17 februari 2014, 08:30
Ansökan om att fördubbla unik studie med Diamyds diabetesvaccin inskickad till Läkemedelsverket
Events & Mediawatch
April 07, 2014, Sweden
sverigesradio.se: Fler unga får typ-1 diabetes
Diabetes typ-1 är betydligt vanligare bland tonåringar och unga vuxna i Sverige än man hittills trott. Nya beräkningar visar att tre...
April 07, 2014, Sweden
dn.se: Okänd miljöfaktor ger fler diabetesfall
En ny svensk studie visar att antalet unga mellan 15 och 34 år som får diabetes typ 1 är tre gånger fler än man tidigare trott. Den...
February 17, 2014, Sweden
Veckotidningen Allers: "Det kändes som ett slag i ansiktet att min egen dotter var drabbad"
I senaste numret av veckotidningen Allers (nr. 8/2014) intervjuas Diamyd Medicals chef för klinisk utveckling Erika Hillborg om familjens personliga...
January 06, 2014, Sweden
di.se: Galen kursrusning i Diamyd Medical
Diamyd Medicals aktie rusade som mest 32 procent under fredagen på grund av en missuppfattning. Efter ett pressmeddelande från bolaget har kursen...
January 02, 2014, Sweden
UPPDATERAD di.se: Diabetesgåtan på väg mot lösning
KLARGÖRANDE:
Diamyd Medical har ingen direkt koppling till TEDDY-studien som artikeln i Dagens Industri handlar om....
December 09, 2013, Australia
Diamyd at IDS 2013 in Australia
The 13th International Congress of the Immunology of Diabetes Society started this weekend in Lorne outside Melbourne in Australia. Almost 300 delegates from 21...
December 06, 2013, Sweden
New scientific paper on treatment with the diabetes vaccine Diamyd
®
The research group of Professor Johnny Ludvigsson at Linköping university have published a new paper in the scientific journal Diabetes/Metabolism Research and...
November 27, 2013, Sweden
diabetes.se: En helt vanlig ovanlig familj
I Svenska Diabetesförbundets kortfilmsserie "En helt vanlig ovanlig familj" träffar familjen Nyman två framstående experter på typ 1-diabetes: professor Johnny...
Finansiella Rapporter
09 april 2014, 08:30
Delårsrapport II 13/14
